Dr. Mary-Elizabeth Percival
Claim this profileFred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Studies Acute Myelogenous Leukemia
Studies Acute Myeloid Leukemia
3 reported clinical trials
5 drugs studied
Area of expertise
1Acute Myelogenous Leukemia
CD33 positive
Stage I
Stage II
2Acute Myeloid Leukemia
CD33 positive
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Mary-Elizabeth Percival is currently running
Gemtuzumab Ozogamicin
for Acute Myeloid Leukemia
This phase II trial studies the how well fractionated gemtuzumab ozogamicin works in treating measurable residual disease in patients with acute myeloid leukemia. Gemtuzumab ozogamicin is a monoclonal antibody, called gemtuzumab, linked to a chemotherapy drug, called ozogamicin. Gemtuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD33 receptors, and delivers a chemotherapy known as calicheamicin to kill them.
Recruiting1 award Phase 2
FLAG-Ida + Pivekimab
for Acute Myeloid Leukemia
This phase I trial finds the best dose of PVEK when given together with fludarabine, cytarabine, granulocyte colony-stimulating factor (G-CSF), and idarubicin, (FLAG-Ida) regimen and studies the effectiveness of this combination therapy in treating patients with newly diagnosed adverse risk acute myeloid leukemia (AML) and other high-grade myeloid neoplasms. PVEK is a monoclonal antibody linked to a chemotherapy drug. PVEK is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD123 receptors, and delivers the chemotherapy drug to kill them. Chemotherapy drugs, such as idarubicin, fludarabine, high-dose cytarabine work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. G-CSF helps the bone marrow make more white blood cells in patients with low white blood cell count due to cancer treatment. Giving PVEK with the FLAG-Ida regimen may be a safe and effective treatment for patients with acute myeloid leukemia and other high-grade myeloid neoplasms.
Recruiting1 award Phase 113 criteria
More about Mary-Elizabeth Percival
Clinical Trial Related6 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Mary-Elizabeth Percival has experience with
- Gemtuzumab Ozogamicin
- FLAG-Ida
- Pivekimab Sunirine
- 5-azacitidine
- APG-115
Breakdown of trials Mary-Elizabeth Percival has run
Acute Myelogenous Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Monocytic Leukemia
Biphenotypic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mary-Elizabeth Percival specialize in?
Mary-Elizabeth Percival focuses on Acute Myelogenous Leukemia and Acute Myeloid Leukemia. In particular, much of their work with Acute Myelogenous Leukemia has involved CD33 positive patients, or patients who are Stage I.
Is Mary-Elizabeth Percival currently recruiting for clinical trials?
Yes, Mary-Elizabeth Percival is currently recruiting for 3 clinical trials in Seattle Washington. If you're interested in participating, you should apply.
Are there any treatments that Mary-Elizabeth Percival has studied deeply?
Yes, Mary-Elizabeth Percival has studied treatments such as Gemtuzumab Ozogamicin, FLAG-Ida, Pivekimab Sunirine.
What is the best way to schedule an appointment with Mary-Elizabeth Percival?
Apply for one of the trials that Mary-Elizabeth Percival is conducting.
What is the office address of Mary-Elizabeth Percival?
The office of Mary-Elizabeth Percival is located at: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington 98109 United States. This is the address for their practice at the Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.